Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies

European Journal of Cancer

Volumn 40, Issue 9, 2004, Pages 1404-1411

  Christov, K T ^a   Moon, R C ^a   Lantvit, D D ^a   Boone, C W ^b   Kelloff, G J ^b   Steele, V E ^b   Lubet, R A ^b   Pezzuto, J M ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Chemoprevention; Noble rats; PIN; Prostate carcinogenesis

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EFLORNITHINE; ESTRADIOL; FLUASTERONE; OLTIPRAZ; PRASTERONE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RAT; SEMINAL VESICLE;

ANIMALS; ANTINEOPLASTIC AGENTS; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EFLORNITHINE; ESTRADIOL; MALE; MODELS, ANIMAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PYRAZINES; RATS; RATS, INBRED STRAINS; TESTOSTERONE; TIME FACTORS;

EID: 2942550645     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2003.11.037     Document Type: Article

References (34)

1. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics. CA Cancer J. Clin. 65:1996;5-27
2. Potoski A.L., Miller B.A., Albertsen P.C., Kramer B.S. The role of increasing detection in the rising incidence of prostate cancer. J. Am. Med. Assoc. 273:1995;548-552
3. Ko Y.J., Bubley G.J. Prostate cancer in older man. Oncology. 15(9):2001;1113-1119
4. Karp J.E., Chiarodo A., Brawley O., Kelloff G.J. Prostate cancer prevention: investigational approaches and opportunities. Cancer Res. 56:1996;5547-5556
5. Bosland M.C. Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur. Urol. 35:1999;459-463
6. Bosland M.C. Animal models for the study of prostate carcinogenesis. J. Cell Biochem. Suppl. 16H:1992;89-98
7. Cohen M.B., Lubaroff M.D. Gross and microscopic pathology of induced prostatic complex in Lobund-Wistar rats. Cancer Res. 54:1994;626-628
8. Pollard M., Luckert P.H. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone. J. Natl. Cancer Inst. 77:1986;583-587
9. Bosland M.C., Prinsen M.K. Induction of dorsolateral prostate adenocarcinoma in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7, 12-dimethylbenz(a) anthracene and 3, 2-dimethyl-4-aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res. 50:1990;691-699
10. McCormic D.L., Rao K.V.N., Dooly L., Steele V.E., Lubet R.A., Kelloff G.J., et al. Influence of N-methyl-nitrosourea, and 4-(hydroxyphenyl)retinamide on prostate cancer induction in Wistar-Unilever rats. Cancer Res. 58:1998;3282-3288
11. Price D. Comparative aspects of development and structure of the prostate. Natl. Cancer Inst. Monogr. 12:1963;1-27
12. McNeal J.E., Bostwick D.G. Intraductal dysplasia: a pre-malignant lesion of the prostate. Hum. Pathol. 17:1986;64-71
13. Podsypanina K., Ellenson L.H., Nemes A., Gu J., Tamura M., Yamada K.M., et al. Mutation of Pten/Mmac 1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA. 96:1999;1563-1568
14. Gupta S., Ahmad N., Marengo S.R., MacLennan G.T., Greenberg N.M., Makhtar H. Chemoprevention of prostate carcinogenesis by α-difluoromethylornitine in TRAMP mice. Cancer Res. 60:2000;5125-5133
15. Noble R.L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 37:1977;1927-1933
16. Noble R.L. Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res. 40:1980;3547-3550
17. Drago J. The induction of Nb rat prostatic carcinomas. Anticancer Res. 4:1984;255-256
18. Leav I., Ho S.-M., Ofner P., Merk F.B., Kwan P.W.-L., Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl. Cancer Inst. 80:1988;1045-1053
19. Leav I., Merk F.B., Kwan P.W.-L., Ho S.-M. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. The Prostate. 15:1989;23-40
20. Christov K.T., Moon R., Lantvit D., Boone C., Steele V.E., Lubet R.A., et al. 9-cis retinoic acid but not 4-(hydroxyphenyl) retinamide inhibits the prostate intraepithelial neoplasia in Noble rats. Cancer Res. 62:2002;5178-5182
21. Ratko T.A., Detrisac C.J., Mehta R.G., Kelloff G.J., Moon R.C. Inhibition of rat mammary gland chemical carcinogenesis by dietary dehydroepiandrosterone or a fluorinated analogue dehydroepiandrosterone. Cancer Res. 51:1991;481-486
22. Schwartz A., Pashko L. Mechanism of cancer prevention action of DHEA. Ann. NY Acad. Sci. 774:1995;180-186
23. Kadman D. Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO). J. Cell Biochem. H. 16(Suppl.):1992;122-127
24. Moon R.C., Rao K.V.N., Detrisac C.J., Kelloff G.J., Steele V.E., Doody L.A. Chemoprevention of respiratory tract neoplasia in the hamster by oltipraz, alone and in combination. Int. J. Oncol. 4:1994;661-667
25. ′ -dimethyl-4-aminobiphenyl, following sequential treatment with cyproterone acetate and testosterone propionate Cancer Res. 50:1990;700-709
26. Snedecor G.J.W., Cochran W.G. 8th ed. Statistical methods. vol. 11:1998;Iowa State University Press, Ames IA. [Chapter 19]
27. McCormick D.L., Rao K.V.N., Johnson W.D., Bowman-Gram T.A., Steele V., Lubet R.A., et al. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland. Cancer Res. 56:1996;1724-1726
28. Rao K.V.N., Johnson W.D., Bosland M.C., Lubet R.A., Steele V.E., Kelloff G.J., et al. Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 59:1999;3084-3089
29. Dorgan J.F., Stanczyk F.Z., Longscope C., Stephenson H.E., Chang L., Miller R., et al. Relationship of serum dehydroepiandrosterone (DHEA) dehydroepiandrosterone sulfate and 5-androstene-β, 17-β-diol to risk of breast cancer in postmenopausal women. Cancer Epidem. Biomark Prev. 6:1997;177-181
30. Lubet R.L., Gordon G.B., Prough R.A., Lei X.D., You M., Wang Y., et al. Modulation of methylnitrosourea-induced breast cancer in Sprague-Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effect of limited exposure, effects on peroxysomal enzymes, and lack of effects on levels of Ha-Ras mutations. Cancer Res. 58:1998;921-926
31. Leighton B., Tagliaferro A.R., Newsholme E.A. The effect of dehydroepiandrosterone acetate on liver peroxysomal enzyme activities on male and female rats. J. Nutr. 117:1987;1287-1290
32. Schulz S., Nyce J.W. Inhibition of farnasyltransferase: a possible mechanism of tumor prevention by dehydroepiandrosterone sulfate. Carcinogenesis. 15:1994;2649-2655
33. Christov K., Moon R.C., Boone C., Lantvit D., Steele V.E., Lubet R.A., et al. 9-cis-Retinoic acid but not 4-(Hydroxyphenyl) ratinamide inhibits the prostate intraepithelial neoplasia (PIN) in Noble rats. Cancer. Res. 62:2002;5178-5182
34. Bosland M.C. Hormonal factors in carcinogenesis of the prostate and testis in humans and in animal models. Huff F., Boyd J., Barrett J.C. Cellular and molecular mechanisms of hormonal carcinogenesis: environmental Influences. 1996;309-352 Wiley-Liss Inc. London